Technology
Health
Biotechnology

AVROBIO

$22.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.78 (3.52%) As of 10:33 AM EDT today
+$0.78 (3.52%) Today

Why Robinhood?

You can buy or sell AVROBIO and other stocks, options, ETFs, and crypto commission-free!

About AVRO

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. Read More These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.

Employees
49
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
526.75M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
984.07K
High Today
$23.30
Low Today
$21.96
Open Price
$22.10
Volume
233.88K
52 Week High
$53.70
52 Week Low
$11.85

Collections

Technology
Health
Biotechnology
Gene Therapies
Therapy
2018 IPO
US
North America

AVRO Earnings

-$2.98
-$2.15
-$1.32
-$0.49
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.